XML 67 R57.htm IDEA: XBRL DOCUMENT v3.22.2.2
Subsequent Events (Details) - USD ($)
$ / shares in Units, $ in Thousands
1 Months Ended 9 Months Ended
Nov. 14, 2022
Oct. 31, 2022
Sep. 30, 2022
Dec. 31, 2021
Subsequent Event [Line Items]        
Total contract amount     $ 0 $ 17
Restricted stock        
Subsequent Event [Line Items]        
Granted (in shares)     147,475  
Subsequent event | 2017 Long Term Incentive Plan | Restricted stock        
Subsequent Event [Line Items]        
Granted (in shares)   4,900    
Subsequent event | Royalty revenue from sales of NARCAN        
Subsequent Event [Line Items]        
Total contract amount $ 25,000      
Subsequent event | Indivior PLC | OPIANT PHARMACEUTICALS, INC.        
Subsequent Event [Line Items]        
Share price (in dollars per share) $ 20.00      
Cash consideration $ 145,000      
Share price, CVR (in dollars per share) $ 8.00      
Subsequent event | Indivior PLC | OPIANT PHARMACEUTICALS, INC. | Contingent Value Rights        
Subsequent Event [Line Items]        
CVR liability, maximum amount $ 67,000      
Subsequent event | Indivior PLC | OPIANT PHARMACEUTICALS, INC. | Contingent Value Right, Scenario 1        
Subsequent Event [Line Items]        
Share price, CVR (in dollars per share) $ 2.00      
CVR liability $ 225,000      
Subsequent event | Indivior PLC | OPIANT PHARMACEUTICALS, INC. | Contingent Value Right, Scenario 2        
Subsequent Event [Line Items]        
Share price, CVR (in dollars per share) $ 2.00      
CVR liability $ 300,000      
Subsequent event | Indivior PLC | OPIANT PHARMACEUTICALS, INC. | Contingent Value Right, Scenario 3        
Subsequent Event [Line Items]        
Share price, CVR (in dollars per share) $ 2.00      
CVR liability $ 325,000      
Subsequent event | Indivior PLC | OPIANT PHARMACEUTICALS, INC. | Contingent Value Right, Scenario 4        
Subsequent Event [Line Items]        
Share price, CVR (in dollars per share) $ 2.00      
CVR liability $ 250,000